These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 18836716)
1. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity. Whittington PJ; Radkevich-Brown O; Jacob JB; Jones RF; Weise AM; Wei WZ Cancer Immunol Immunother; 2009 May; 58(5):759-67. PubMed ID: 18836716 [TBL] [Abstract][Full Text] [Related]
2. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573 [TBL] [Abstract][Full Text] [Related]
3. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Jacob JB; Kong YC; Meroueh C; Snower DP; David CS; Ho YS; Wei WZ Cancer Res; 2007 Jul; 67(14):7020-7. PubMed ID: 17638915 [TBL] [Abstract][Full Text] [Related]
4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. Pilon SA; Piechocki MP; Wei WZ J Immunol; 2001 Sep; 167(6):3201-6. PubMed ID: 11544306 [TBL] [Abstract][Full Text] [Related]
6. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. Renard V; Sonderbye L; Ebbehøj K; Rasmussen PB; Gregorius K; Gottschalk T; Mouritsen S; Gautam A; Leach DR J Immunol; 2003 Aug; 171(3):1588-95. PubMed ID: 12874253 [TBL] [Abstract][Full Text] [Related]
7. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. Piechocki MP; Pilon SA; Wei WZ J Immunol; 2001 Sep; 167(6):3367-74. PubMed ID: 11544327 [TBL] [Abstract][Full Text] [Related]
8. Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice. Radkevich-Brown O; Jacob J; Kershaw M; Wei WZ Cancer Res; 2009 Jan; 69(1):212-8. PubMed ID: 19118005 [TBL] [Abstract][Full Text] [Related]
9. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911 [TBL] [Abstract][Full Text] [Related]
10. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice. Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328 [TBL] [Abstract][Full Text] [Related]
11. HER-2/neu as a target for cancer vaccines. Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929 [TBL] [Abstract][Full Text] [Related]
12. The "A, B and C" of Her-2 DNA vaccine development. Wei WZ; Jacob J; Radkevich-Brown O; Whittington P; Kong YC Cancer Immunol Immunother; 2008 Nov; 57(11):1711-7. PubMed ID: 18273615 [TBL] [Abstract][Full Text] [Related]
13. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474 [TBL] [Abstract][Full Text] [Related]
14. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384 [TBL] [Abstract][Full Text] [Related]
15. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Eiben GL; Velders MP; Schreiber H; Cassetti MC; Pullen JK; Smith LR; Kast WM Cancer Res; 2002 Oct; 62(20):5792-9. PubMed ID: 12384540 [TBL] [Abstract][Full Text] [Related]
16. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909 [TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348 [TBL] [Abstract][Full Text] [Related]
19. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. Jacob JB; Kong YC; Nalbantoglu I; Snower DP; Wei WZ J Immunol; 2009 May; 182(9):5873-81. PubMed ID: 19380836 [TBL] [Abstract][Full Text] [Related]
20. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]